Method for predicting the response and survival from chemotherapy in patients with breast cancer

摘要

A method for predicting the residual risk of recurrence after standard chemotherapy treatment, in particular a taxane-free chemotherapy, and the benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method comprises the steps of: (a) determining in a tumor sample from said patient the expression levels of the following 6 genes: UBE2C, KIF20A, PTGER3, OSBPL1A, CYP27A1, IGKC, and (b) mathematically combining said expression level values for the genes of the said set which values were determined in the tumor sample to yield a prognostic combined score and (c) comparing said prognostic combined score to one or more thresholds and classifying said patient in a good, intermediate or poor outcome group and (d) determining in said tumor sample from said patient the expression levels of three genes: STC1, PCSK6, S100P, and (e) mathematically combining said expression level values for STC1, PCSK6 and S100P to yield a predictive combined score, whereas a high predictive combined score generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen in a patient classified to said poor and/or intermediate outcome group.